Key clinical point: When given after transplant, azithromycin does not increase the risk of relapse in patients with moderate to severe chronic graft-versus-host disease and bronchiolitis obliterans syndrome, according to a retrospective study.
Major finding: The 2-year relapse rate was significantly lower in patients who received azithromycin than in those who did not – 4% and 17%, respectively (P = .001).
Study details: A retrospective study of 239 patients
Disclosures: The speaker reported no conflicts of interest.
Shamoun M et al. TCT 2019, Abstract 33.
This Week's Must Reads
Must Reads in Leukemia, Myelodysplasia, Transplantation
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9